Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is listed today as Tyra Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2024 | $200 M | Private placement after listing | $50 to $250 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tyra Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).
SEC Form D · Feb 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2024
That is all the official record says: Tyra Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Tyra Biosciences, Inc. are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Partners NextGen Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Alta Partners NextGen Fund II Management, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Boxer Asset Management Inc. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Boxer Capital, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Canaan 2020+ Co-Investment L.P. Series 7 | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Canaan Partners 2020+ Co-Investment LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Canaan Partners XI LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Canaan XI L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Daniel Bensen | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2021) | SEC Form 3 |
| Isan Chen | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| MVA Investors, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| RA Capital Nexus Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Todd Harris | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Tyra Biosciences, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$267 M17.66%
- FMR LLC$230 M15.25%
- Janus Henderson Group Ltd.$115 M7.62%
- BVF Inc/il$92 M6.10%
- Alta Partners Management Company, L.P.$84 M5.53%
- Paradigm Biocapital Advisors LP$77 M5.08%
- TCG Crossover Management, LLC$76 M5.03%
- Nextech Invest Ltd.$75 M4.99%
- Siren, L.L.C.$74 M4.92%
- BlackRock, Inc.$73 M4.86%
- Price T Rowe Associates Inc /MD/$56 M3.73%
- State Street Corp$44 M2.89%
- Vanguard Capital Management LLC$39 M2.56%
- Commodore Capital LP$38 M2.50%
- Geode Capital Management, LLC$23 M1.50%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alan Fuhrman | Executive officer | Feb 2024 |
| Daniel Bensen | Executive officer | Feb 2024 |
| Hiroomi Tada, M.D., Ph.D. | Executive officer | Feb 2024 |
| Todd Harris, Ph.D. | Executive officer | Feb 2024 |
| Gilla Kaplan, Ph.D. | Director | Feb 2024 |
| Isan Chen, M.D. | Director | Feb 2024 |
| Jake Simson, Ph.D. | Director | Feb 2024 |
| Melissa McCracken, Ph.D. | Director | Feb 2024 |
| Nina Kjellson | Director | Feb 2024 |
| Rehan Verjee | Director | Feb 2024 |
| Robert More | Director | Feb 2024 |
| Sid Subramony, Ph.D. | Director | Feb 2024 |
| Todd Harris, Ph.D. | Director | Feb 2024 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.